First Time Loading...

Ekso Bionics Holdings Inc
NASDAQ:EKSO

Watchlist Manager
Ekso Bionics Holdings Inc Logo
Ekso Bionics Holdings Inc
NASDAQ:EKSO
Watchlist
Price: 1.36 USD -4.23% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

EKSO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. [ Read More ]

The intrinsic value of one EKSO stock under the Base Case scenario is 1.78 USD. Compared to the current market price of 1.36 USD, Ekso Bionics Holdings Inc is Undervalued by 23%.

Key Points:
EKSO Intrinsic Value
Base Case
1.78 USD
Undervaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ekso Bionics Holdings Inc

Backtest EKSO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EKSO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Ekso Bionics' Record-Revenue Growth and Efficiency
2023-Q4 Earnings Call

Ekso Bionics' Record-Revenue Growth and Efficiency

In 2023, Ekso Bionics achieved record annual revenues, hitting $18.3 million, a surge by 42% from 2022. This robust growth included a substantial 51% increase in EksoHealth devices sold, totaling 151 units. The fourth quarter alone saw revenues rise by 36% to $4.8 million, attributed to robust sales in EksoNR and Indego devices. Notably, the company launched GaitCoach software, expected to amplify utilization, and faced deferred payment determinations from CMS for its Indego Personal exoskeleton, promising ongoing efforts to secure a reimbursement rate. Internationally, sales soared across EMEA and APAC regions, with operational advancements such as the collaboration with high-volume manufacturers to lower costs. Despite revenue soaring, operating expenses grew only 11%, demonstrating impressive operational efficiency and a 3% inventory reduction.

Financials

Balance Sheet Decomposition
Ekso Bionics Holdings Inc

Current Assets 20.2m
Cash & Short-Term Investments 8.6m
Receivables 5.6m
Other Current Assets 5.9m
Non-Current Assets 8.7m
PP&E 3m
Intangibles 5.3m
Other Non-Current Assets 392k
Current Liabilities 8.1m
Accounts Payable 1.8m
Accrued Liabilities 3m
Other Current Liabilities 3.2m
Non-Current Liabilities 8.2m
Long-Term Debt 4.8m
Other Non-Current Liabilities 3.4m
Efficiency

Earnings Waterfall
Ekso Bionics Holdings Inc

Revenue
18.3m USD
Cost of Revenue
-9.2m USD
Gross Profit
9.1m USD
Operating Expenses
-24.2m USD
Operating Income
-15.1m USD
Other Expenses
-86k USD
Net Income
-15.2m USD

Free Cash Flow Analysis
Ekso Bionics Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EKSO Profitability Score
Profitability Due Diligence

Ekso Bionics Holdings Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Ekso Bionics Holdings Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

EKSO Solvency Score
Solvency Due Diligence

Ekso Bionics Holdings Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
41/100
Solvency
Score

Ekso Bionics Holdings Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EKSO Price Targets Summary
Ekso Bionics Holdings Inc

Wall Street analysts forecast EKSO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EKSO is 9.25 USD .

Lowest
Price Target
Not Available
Average
Price Target
9.25 USD
580% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EKSO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EKSO Price
Ekso Bionics Holdings Inc

1M 1M
-28%
6M 6M
+86%
1Y 1Y
-7%
3Y 3Y
-77%
5Y 5Y
-96%
10Y 10Y
-100%
Annual Price Range
1.36
52w Low
0.67
52w High
3.1
Price Metrics
Average Annual Return -46.78%
Standard Deviation of Annual Returns 37.62%
Max Drawdown -98%
Shares Statistics
Market Capitalization 24.3m USD
Shares Outstanding 17 903 100
Percentage of Shares Shorted 0.85%

EKSO Return Decomposition
Main factors of price return

What is price return decomposition?

EKSO News

Other Videos

Company Profile

Ekso Bionics Holdings Inc Logo
Ekso Bionics Holdings Inc

Country

United States of America

Industry

Health Care

Market Cap

24.3m USD

Dividend Yield

0%

Description

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in Richmond California, California and currently employs 45 full-time employees. The company went IPO on 2013-04-10. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The firm operates in two segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform repetitive work. Its products include EksoNR and EksoUE. EksoNR is a rehabilitation device that assists physical therapists and physicians to treat patients who have suffered an acquired brain injury, stroke or spinal cord injury. EksoUE is a wearable upper body exoskeleton that assists patients with a broad range of upper extremity impairments.

Contact

CALIFORNIA
Richmond California
1414 Harbour Way S Ste 1201
+15109841761.0
https://ir.eksobionics.com/

IPO

2013-04-10

Employees

45

Officers

CEO & Director
Mr. Scott G. Davis
Corporate Controller, Corporate Secretary & CFO
Mr. Jerome Wong
Chief Operating Officer
Mr. Jason C. Jones
Global Director of Marketing & Strategic Growth
Ms. Rachael Anderson
Vice President of Sales
Mr. Anthony Pratt
Human Resources Director
Ms. Ann Cookson
Show More
President of APAC
Ms. Foon Lim Chwee
Senior VP & GM of EMEA
Mr. Stephan Aderhold
Show Less

See Also

Discover More
What is the Intrinsic Value of one EKSO stock?

The intrinsic value of one EKSO stock under the Base Case scenario is 1.78 USD.

Is EKSO stock undervalued or overvalued?

Compared to the current market price of 1.36 USD, Ekso Bionics Holdings Inc is Undervalued by 23%.